Drug Discovery Today
SEPTEMBER 16, 2021
A drug already used to treat high blood pressure could be re-purposed as the first treatment to tackle a type of vascular dementia caused by damaged and ‘leaky’ small blood vessels in the brain, according to research part-funded by the British Heart Foundation and published today in the Journal of Clinical Investigation.
Drug Patent Watch
SEPTEMBER 14, 2021
Annual Drug Patent Expirations for ANORO+ELLIPTA Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fourteen patents…. The post New patent for Glaxosmithkline drug ANORO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
SEPTEMBER 14, 2021
On October 5, 2021, Drug Channels Institute will release The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our twelfth edition— remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. We are providing you with the opportunity to preorder this thoroughly updated and revised 2021-22 edition at special discounted prices.
Olympian Clinical Research
SEPTEMBER 16, 2021
Affecting more than 3% of the United States population, psoriasis is a skin disorder that causes red, raised patches of skin covered with thick flakes. It can have a considerably negative impact on a person’s quality of life and psychological well-being. The patches typically appear on the elbows, knees or scalp. While it is most common in adults, a third of psoriasis cases can also be found in children, which is known as pediatric psoriasis. .
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Discovery Today
SEPTEMBER 16, 2021
Demand for Touchlight’s synthetic DNA vector has grown rapidly since last year.dbDNA™ is driving biomedical innovations such as DNA and mRNA vaccines, synthetic DNA-based neutralising antibody therapies, and more.Touchlight’s synthetic DNA vector is revolutionising genetic medicine manufacture by offering a superior alternative to traditional plasmid DNA.
Drug Patent Watch
SEPTEMBER 14, 2021
Annual Drug Patent Expirations for ZYVOX Zyvox is a drug marketed by Pfizer and is included in three NDAs. It is available from four suppliers. There are two patents protecting…. The post New patent expiration for Pfizer drug ZYVOX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Practical Cheminformatics
SEPTEMBER 12, 2021
In this post, we're going to take a look at molecular similarity searches. Molecular similarity is central to a lot of what we do in Cheminformatics. It's important for identifying analogs and understanding SAR. Molecular similarity is also at the core of many clustering methods that we use to understand datasets or design screening libraries. In this example, we'll be using the chemfp package by Andrew Dalke.
The Pharma Data
SEPTEMBER 11, 2021
– Designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with preserved ejection fraction. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance ® (empagliflozin) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer
Drug Patent Watch
SEPTEMBER 16, 2021
This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
SEPTEMBER 17, 2021
Today’s guest post comes from Vicki Muscarella, Vice President of Specialty at CoverMyMeds. Vicki discusses the advantages of integrated technology solutions in enhancing specialty patients' access to therapy, affordability, and adherence. CoverMyMeds now includes RelayHealth, RxCrossroads by McKesson, and McKesson Prescription automation. Click here to sign up for complimentary early access to the specialty edition of the CoverMyMeds 2021 Medication Access Report.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Crown Bioscience
SEPTEMBER 14, 2021
Accelerating cancer drug discovery with digital pathology-based biomarker analysis is transforming the field of modern pathology.
The Pharma Data
SEPTEMBER 11, 2021
Eli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG) strategy to increase access to medicines, improve lives and communities, empower a diverse workforce, minimize environmental impact and operate ethically and responsibly. The company is issuing €600 million in aggregate principal amount of 0.50% notes with 12-year maturity, subject to customary closing conditions. “Lilly is taking
Drug Patent Watch
SEPTEMBER 15, 2021
Annual Drug Patent Expirations for ENTRESTO Entresto is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Novartis Pharms drug ENTRESTO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
SEPTEMBER 13, 2021
Informa Connect’s Drug Pricing Transparency Congress. Delivered as a Hybrid Event In-Person: November 9-10 | Philadelphia, PA Virtual: November 16-17 www.informaconnect.com/drug-pricing-transparency. Save 10% by using code 21DPT10. The 2021 Drug Pricing Transparency Congress , an important event dedicated to providing critical updates on federal and state reporting requirements, policy initiatives and strategic best practices for compliance, returns this November as a HYBRID event, with the in-p
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
SEPTEMBER 13, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 15, 2021
This chart shows the drugs with the most patents in Singapore. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Singapore? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 14, 2021
This chart shows the pharmaceutical companies with the most patents in Iceland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Iceland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 12, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
SEPTEMBER 11, 2021
This chart shows the drugs with the most patents in Japan. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Japan? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 11, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 17, 2021
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharma companies have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 17, 2021
Annual Drug Patent Expirations for ENVARSUS+XR Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Veloxis Pharms drug ENVARSUS XR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 17, 2021
Annual Drug Patent Expirations for EPIDIOLEX Epidiolex is a drug marketed by Gw Res Ltd and is included in one NDA. It is available from one supplier. There are sixteen…. The post New patent for Gw Res drug EPIDIOLEX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 14, 2021
Annual Drug Patent Expirations for TRELEGY+ELLIPTA Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are nineteen patents…. The post New patent for Glaxosmithkline drug TRELEGY ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 14, 2021
Annual Drug Patent Expirations for LILETTA Liletta is a drug marketed by Medicines360 and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent for Medicines360 drug LILETTA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 13, 2021
Annual Drug Patent Expirations for JEVTANA+KIT Jevtana Kit is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from one supplier. There are…. The post New patent for Sanofi Aventis drug JEVTANA KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 13, 2021
Annual Drug Patent Expirations for UPNEEQ Upneeq is a drug marketed by Rvl Pharms and is included in one NDA. There are seven patents protecting this drug. This drug has…. The post New patent for Rvl Pharms drug UPNEEQ appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 13, 2021
Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Zogenix Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 13, 2021
Annual Drug Patent Expirations for NATESTO Natesto is a drug marketed by Acerus and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent for Acerus drug NATESTO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 13, 2021
Annual Drug Patent Expirations for ROZLYTREK Rozlytrek is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There are twelve patents…. The post New patent for Genentech Inc drug ROZLYTREK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 13, 2021
Annual Drug Patent Expirations for QDOLO Qdolo is a drug marketed by Athena and is included in one NDA. The generic ingredient in QDOLO is tramadol hydrochloride. Additional details are…. The post New patent for Athena drug QDOLO appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
SEPTEMBER 11, 2021
Bristol Myers Squibb today announced findings from a global real-world evidence study that the risk of mortality increases with worse New York Heart Association functional class (NYHA class) for patients with obstructive hypertrophic cardiomyopathy (obstructive HCM). While other studies have documented this association in HCM, this study represents one of the largest, multi-centered studies that specifically focuses on the obstructive HCM patient population.
The Pharma Data
SEPTEMBER 11, 2021
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim.
Expert insights. Personalized for you.
178 
Let's personalize your content